Daily Sepsis Research Analysis
Evidence from a network meta-analysis suggests esmolol likely reduces 28-day mortality in sepsis compared with standard care and may outperform landiolol, which was associated with higher norepinephrine needs. Two mechanistic studies illuminate new therapeutic avenues: inhibiting the DYNLL2–PAK1 axis to dampen caspase-11-dependent pyroptosis, and leveraging Akkermansia muciniphila to reverse endotoxin-tolerant, immunosuppressed macrophage phenotypes.
Summary
Evidence from a network meta-analysis suggests esmolol likely reduces 28-day mortality in sepsis compared with standard care and may outperform landiolol, which was associated with higher norepinephrine needs. Two mechanistic studies illuminate new therapeutic avenues: inhibiting the DYNLL2–PAK1 axis to dampen caspase-11-dependent pyroptosis, and leveraging Akkermansia muciniphila to reverse endotoxin-tolerant, immunosuppressed macrophage phenotypes.
Research Themes
- Hemodynamic modulation in sepsis with short-acting beta-blockers
- Targeting pyroptosis and innate immune signaling (DYNLL2–PAK1–caspase-11)
- Microbiome-immune crosstalk to reverse sepsis-induced immunosuppression
Selected Articles
1. Comparison of Esmolol Versus Landiolol on Mortality in Adult Patients With Sepsis: A Systematic Review and Network Meta-Analysis.
Across 10 RCTs (n=1,035), esmolol reduced 28-day mortality (RR 0.69, 95% CI 0.56–0.85) and heart rate versus standard care, while landiolol increased norepinephrine requirements versus SOC and was associated with higher 28-day mortality compared with esmolol (RR 1.57, 95% CI 1.08–2.30). Certainty was moderate for esmolol effects and low for landiolol comparisons.
Impact: Provides comparative effectiveness evidence on short-acting β-blockers in sepsis, suggesting esmolol may confer survival benefit while landiolol may increase vasopressor needs.
Clinical Implications: Consider esmolol as the preferred short-acting β-blocker in septic patients requiring heart rate control, with close hemodynamic monitoring and awareness of catecholamine requirements; avoid extrapolating landiolol benefits until higher-certainty data are available.
Key Findings
- Esmolol reduced 28-day mortality versus standard care (RR 0.69, 95% CI 0.56–0.85; moderate certainty).
- Esmolol lowered 24-hour heart rate versus standard care (MD −16.92 bpm, 95% CI −23.49 to −10.36; moderate certainty).
- Landiolol increased norepinephrine use compared with standard care (MD 0.09 μg/kg/min, 95% CI 0.01–0.18; moderate certainty).
- Landiolol was associated with higher 28-day mortality versus esmolol (RR 1.57, 95% CI 1.08–2.30; low certainty).
Methodological Strengths
- Network meta-analysis of randomized controlled trials with explicit certainty ratings.
- Comprehensive multi-database search including registries and citation tracking.
Limitations
- Low certainty for landiolol comparisons and potential heterogeneity in dosing strategies.
- Limited head-to-head trials between esmolol and landiolol.
Future Directions: Conduct adequately powered head-to-head RCTs of esmolol versus landiolol with standardized titration protocols and patient-centered outcomes, and mechanistic studies to explain differential vasopressor effects.
OBJECTIVES: The clinical efficacy of short-acting β-blockers in the management of sepsis remains uncertain. In particular, the comparative effects of two commonly used agents-esmolol and landiolol-have not been clearly established. This network meta-analysis aims to systematically evaluate and compare the effects of esmolol, landiolol, and standard of care (SOC) on mortality in patients with sepsis. DATA SOURCES: A systematic search of PubMed, Web of Science, Embase, MEDLINE, CENTRAL, ClinicalTrials.gov, preprints, and citation searching was conducted before April 15, 2025. STUDY SELECTION: Randomized controlled trials that enrolled adult patients (≥ 18 yr) diagnosed with sepsis or septic shock and treated with β-blockers and conducted in ICUs. DATA EXTRACTION: Data were extracted on study characte
2. Targeting the DYNLL2-PAK1 axis inhibits caspase-11-dependent pyroptosis to alleviate sepsis.
DYNLL2 was identified as a driver of sepsis severity and monocyte expansion; it partners with PAK1 to promote OMV uptake, cytosolic LPS release, and caspase-11/GSDMD-mediated pyroptosis. Pharmacologic disruption with Oroxylin A reduced cytosolic LPS, blunted pyroptosis, improved survival, and mitigated organ injury in murine endotoxemia models.
Impact: Reveals a tractable immune-metabolic axis controlling cytosolic LPS sensing and pyroptosis, and proposes an orally relevant small-molecule inhibitor as a therapeutic lead.
Clinical Implications: While preclinical, targeting DYNLL2–PAK1 could complement antimicrobial therapy by limiting caspase-11-dependent pyroptosis and systemic inflammation without impairing bacterial clearance.
Key Findings
- DYNLL2 expression is elevated in sepsis and correlates with poor prognosis and monocyte expansion.
- DYNLL2 interacts with PAK1 to promote OMV endocytosis, increasing cytosolic LPS and caspase-11/GSDMD activation.
- Genetic depletion of DYNLL2 or PAK1 suppresses OMV internalization and downstream pyroptosis without reducing bacterial clearance.
- Oroxylin A blocks the DYNLL2–PAK1 interaction, reduces cytosolic LPS, and improves survival and organ injury in murine endotoxemia.
Methodological Strengths
- Integrates clinical bioinformatics with mechanistic validation (in vitro and in vivo).
- Identifies and tests a small-molecule inhibitor with functional outcomes in disease models.
Limitations
- Primary in vivo evidence in endotoxemia rather than polymicrobial sepsis (e.g., CLP).
- No human interventional validation of Oroxylin A safety/efficacy.
Future Directions: Validate the DYNLL2–PAK1 axis in CLP and bacterial sepsis models, delineate pharmacokinetics/toxicology of Oroxylin A, and progress to first-in-human studies with pharmacodynamic biomarkers of pyroptosis.
Sepsis, a life-threatening syndrome caused by dysregulated host responses to infection, lacks effective therapeutic strategies due to its complex immune pathophysiology. Here, we identify Dynein Light Chain LC8-Type 2 (DYNLL2) as a critical risk gene driving sepsis progression through bioinformatics and machine learning analysis of clinical datasets. Elevated DYNLL2 expression correlates with poor prognosis and monocyte expansion in sepsis patients. Mechanistically, DYNLL2 interacts with p21-Acti
3. Akkermansia muciniphila attenuates sepsis-induced immunosuppression by shaping endotoxin-tolerant macrophage phenotype.
In endotoxin-tolerant macrophages, AKK shifted polarization from M2 to M1, enhancing antibacterial capacity. 16S data linked lower AKK abundance with immunosuppression, and in murine endotoxin-tolerance sepsis models, AKK administration alleviated immunosuppression by reprogramming macrophage phenotypes.
Impact: Introduces a microbiome-based strategy to counter sepsis-induced immunosuppression by directly reshaping macrophage phenotypes.
Clinical Implications: Suggests potential for adjunctive probiotic therapy to restore immune competence in septic patients; requires rigorous safety and efficacy trials before clinical adoption.
Key Findings
- Endotoxin-tolerant RAW264.7 macrophages displayed M2 polarization; AKK shifted phenotype toward M1.
- AKK enhanced Pseudomonas aeruginosa clearance in vitro.
- In murine endotoxin tolerance models, AKK administration alleviated sepsis-induced immunosuppression via macrophage phenotype modulation.
- 16S rRNA sequencing associated reduced AKK abundance with immunosuppressed states.
Methodological Strengths
- Convergent evidence from microbiome profiling, cell phenotyping, and in vivo validation.
- Functional readouts (pathogen clearance) linked to macrophage polarization changes.
Limitations
- Use of RAW264.7 cell line and endotoxin tolerance model may not fully recapitulate human sepsis complexity.
- No randomized animal studies comparing live AKK versus components or metabolites; limited translational data.
Future Directions: Test AKK strains, dosing, and timing in CLP and polymicrobial models; dissect molecular mediators (e.g., TLRs, metabolites) and evaluate safety/immunogenicity for clinical translation.
BACKGROUND: Sepsis, a life-threatening condition resulting from a dysregulated host response to infection, is a great menace to public health. One of the primary pathological features of sepsis is immunosuppression, which is largely mediated by endotoxin tolerance. Akkermansia muciniphila (AKK), a gut probiotic, is known to modulate host immune responses. There is a pressing need to explore its potential role in addressing sepsis-induced immunosuppression. METHODS: To assess the abundance of AKK i